Andrew J. Stewart - 24 Apr 2023 Form 4 Insider Report for Bausch & Lomb Corp (BLCO)

Role: The Reporting Person's title as an officer of the Issuer is President, Ophthalmic Pharmaceuticals.
Signature: /s/ Debra E. Levin, attorney-in-fact
Issuer symbol: BLCO
Transactions as of: 24 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 26 Apr 2023, 17:22:38 UTC
Next filing: 01 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BLCO	Common Shares, No Par Value	Award	$0	+33,150		$0.000000	33,150	24 Apr 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the grant of restricted stock units ("RSUs") under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation.

Remarks:

The Reporting Person's title as an officer of the Issuer is President, Ophthalmic Pharmaceuticals.